NCT01314898View on ClinicalTrials.gov

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Healthy Volunteers
Interventions
DRUG

3 mg PF-03882845

3 mg PF-03882845, single oral dose

DRUG

10 mg PF-03882845

10 mg PF-03882845, single oral dose

DRUG

30 mg PF-03882845

30 mg PF-03882845, single oral dose

DRUG

100 mg PF-03882845

100 mg PF-03882845, single oral dose

DRUG

Spironolactone

100 mg spironolactone, single oral dose

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01314898 - A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers | Biotech Hunter | Biotech Hunter